In Brief: Ciba Corning
This article was originally published in The Gray Sheet
Executive Summary
Ciba Corning: Introduces the ACS PSA2 test for prostate specific antigen. The test, used in the management of prostate cancer patients, is the second PSA assay for use on the firm's ACS:180 testing system. Capable of providing initial results in 15 minutes and offering a throughput of up to 180 tests per hour, the ACS PSA2 also features "a direct measurement range up to 135 ng/mL with automated dilution expanding the routine measurable range to 2,700 ng/mL." Ciba Corning introduced its initial ACS test for PSA in September 1994 following premarket approval for use of the test in prostate cancer management ("The Gray Sheet" Sept. 26, 1994, In Brief)...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.